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Abstract
Objective: Rate, reasons and predictors of antiepileptic drugs (AEDs) discontinuation were
investigated in a well-defined cohort of people with epilepsy to verify efficacy and tolerability of
treatment in up to twenty years from treatment initiation.
Methods: The history of AED usage in children and adults with epilepsy registered with 123 family
physicians in an area of Northern Italy between 2000 and 2008 was recorded. Cumulative
probabilities of AED withdrawal for specific reasons were estimated using cumulative incidence
functions. The probabilities of withdrawing for terminal remission, or of achieving sustained
remission while still on treatment, were also evaluated. The roles of sex, age at diagnosis, seizure
types, duration at diagnosis and syndrome were assessed with hazard ratios (HR) and 95%
confidence intervals (95% CI).
Results: 731/747 individuals were treated with one or more AEDs during the disease course. The
three commonest drugs were valproate, carbamazepine and phenobarbital. Reported reasons for
AED withdrawal were, in decreasing order, terminal remission, ineffectiveness and adverse events.
The probability of withdrawing the first AED for terminal remission was 1.0% at one year and
increased to 20.0% at twenty years. Corresponding rates for ineffectiveness were 2.9% and 12.6%;
and for adverse events 0.5% and 3.3 %. Reasons for withdrawal varied with individuals’ age, sex,
disease characteristics, and drugs.
Significance: The initial AED given was retained in the majority of cases. Terminal remission, lack
of efficacy and adverse effects were, in decreasing order, the commonest reasons for AED
discontinuation. Withdrawal could be predicted by age at diagnosis, sex and clinical characteristics
and varies among drugs.
Keywords: Epilepsy, antiepileptic drugs, discontinuation
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Introduction
The response to antiepileptic drugs (AEDs) is an important indicator of the prognosis of epilepsy.
AEDs are generally efficacious in controlling seizures. In randomized trials, but also in clinical
practice, seizure freedom is seen in about 50% of people with previously untreatedepilepsy.1-3 In
people who do not respond to the first AED, the use of a second drug leads to complete seizure
control in a lower proportion of cases and there is a further decrease with each subsequent treatment
change.4-7 If the first drug fails, however, seizure-free rates vary across studies and, although drug-
resistant epilepsy has been defined as the failure of two appropriate AEDs,8 there are reports of
people achieving seizure freedom even after having failed several AEDs.5, 9-11 While withdrawal of
ineffective drugs, when given as first or subsequent treatments, is usually clearly documented, the
information becomes fragmentary regarding the reasons for discontinuation. Additionally, with
some exceptions,12-14 AED retention has not been assessed in a population-based sample. Lastly,
there are no data on the history of AED treatment in samples of children and adults with epilepsy
from the same population and followed for a prolonged period of time.
We investigated rate, reasons and predictors of AED discontinuations in a well-defined population
followed for up to twenty years from treatment start. We aimed: 1. To estimate the retention rate of
AEDs according to the order of administration (first, second, or subsequent) in general and by drug;
2. To investigate the reasons for stopping AEDs with reference to the sequence of drug assignment;
3. To ascertain possible predictors of treatment discontinuation with reference to the commonest
reasons for discontinuing the assigned drug.
Methods
The study sample (146,506; year 2008), representative of the general population, was based in the
province of Lecco, Northern Italy.15,16
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The details of the study design are given elsewhere15,16 and are summarized here. In Italy, the
diagnosis of epilepsy is confirmed by a neurologist who also takes the responsibility to start and,
where needed, to change or stop the treatment. The individual is then followed by his/her general
practitioner (GP) to obtain drugs free-of-charge. One hundred and twenty-three GPs (47% of those
active in the province) were invited to identify people with epilepsy in their practice’s list and who
had lived in the area for at least one year between January 1st 2000 and December 31st 2008. The
medical records of all these individuals in the practice and, if available, in other in- and out-patient
facilities such as hospitals, nursing homes, out-patient clinics were reviewed. Epilepsy diagnosis
was based on a history of two or more unprovoked seizures at least 24 hours apart17 and confirmed
by a neurologist. People with acute symptomatic seizures, neonatal seizures, single unprovoked
seizures, and paroxysmal non-epileptic events were excluded. For each eligible case, data were
collected on demographics (date of birth, sex), predominant seizure types,18 date of diagnosis,
epilepsy syndrome,19 number and type of drugs used since the beginning of treatment. For each
AED, details were collected on starting date, maximal maintenance daily dose, and withdrawal date
or last follow-up date, whichever came earlier. If the drug was discontinued, reasons for
discontinuation (ineffectiveness, adverse events, terminal remission or other) were recorded. As the
study period preceded the new epilepsies classification scheme,20 the 1989 classification19 was used.
As detailed information was not available in all cases, seizures and syndromes were classified
using broad categories. Seizures were classified as focal, generalized, or unclassifiable. Syndromes
were classified as partial (idiopathic, symptomatic, or cryptogenic), generalized (idiopathic or
symptomatic/cryptogenic), undetermined, and special. All data from the GPs and, if needed, from
the consulting neurologists (including those outside the study area) were de-identified and filed in a
central database by two of us (GG and VC) who interacted with the GPs and, if required, with the
neurologists. Two of us (EBe and GE) revised the information included in the database to confirm
the appropriateness of the indications of all drugs assigned to each individual during the disease
course.
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Prevalence and incidence of epilepsy, of drug-resistant epilepsy and prognostic patterns in the same
study population have been previously reported elsewhere.15,16
Statistical analyses were performed using SAS (version 9.2; SAS Institute, Inc, Cary, NC, USA).
Descriptive statistics are presented as counts and percentages. Administration frequencies and
cause-specific withdrawal frequencies were calculated for each active principle and by prescription
order. AEDs were also grouped in two different classes: old and newer (marketed before and after
1990). Old drugs included barbexaclone (BSC), carbamazepine (CBZ), clobazam (CLB),
clonazepam (CNP), ethosuximide (ESM), phenobarbital (PB), phenytoin (PHT), primidone (PRM),
valproate (VPA), valpromide (VPM); newer drugs included gabapentin (GBP), levetiracetam
(LEV), lamotrigine (LTG), oxcarbazepine (OXC), pregabalin (PGB), tiagabine (TGB), topiramate
(TPM), vigabatrin (VGB), zonisamide (ZNS).
To account for competing risks, cumulative probabilities of AED withdrawal from specific causes
over twenty years from treatment start were estimated using cumulative incidence functions. The
cumulative probability of cause-specific AED withdrawal was calculated for the first, second, and
third AED, for the most common AEDs (i.e. used by more than 100 people), and for new and old
AEDs separately. Differences in the cumulative incidence functions between new and old AEDs
were assessed using Gray’s test.21 For the first AED, the cumulative probability of withdrawing for
terminal remission (ie, seizure freedom for at least two years at last follow-up) while still on
treatment, was also evaluated.
The association between drug discontinuation and sex, age at diagnosis (<15, 15-64, 65+ years),
seizure types (focal, generalized, unclassifiable), duration from first seizure to diagnosis, and
epilepsy syndrome (idiopathic, cryptogenic/symptomatic, special/undetermined) was assessed using
the Cox proportional hazards function. Models for the most commonly used AEDs were adjusted
for the number of previous drugs taken. Results were presented as Hazard Ratios (HR) with 95%
Confidence Intervals (95%CI). Missing data were handled using the listwise deletion method.
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The study was approved by the Ethics Committee of the Provincial Hospital of Lecco (Protocol
2011-003428-11). Local Health Service authorization was obtained to collect de-identified data
from the GPs. In less than 5% of cases, the GPs needed to collect additional information from
individuals, after informed consent. All the data were managed according to the current Italian
privacy rules.
Results
The study sample consist of 747 people with epilepsy aged 11 months through 94 years and
followed for a total of 11,045.5 person-years (mean 14.8 years; interquartile range 4.5-22.5).
Clinical characteristics are provided in Table 1; 731 people (98%) were treated with at least one
AED.
The use of each compound as first, second, third, or fourth to ninth AED is shown in Table 2. The
three AEDs most commonly used as first drug were valproate, carbamazepine and phenobarbital
and the same drugs were also the commonest second option. The third option included, in
decreasing order, carbamazepine, levetiracetam and topiramate.
The commonest reasons for drug withdrawal were, in decreasing order, terminal remission,
ineffectiveness and adverse events. Table 3 shows the reasons for withdrawal with reference to the
sequence of drug assignment. For the first AED, the main reasons for withdrawal were terminal
remission followed by ineffectiveness; for the second AED the main reasons were ineffectiveness
followed by terminal remission; for the third and the fourth AED the main reason was
ineffectiveness, followed by adverse events. Withdrawal for ineffectiveness increased from the first
to the seventh drug, while withdrawal for terminal remission decreased progressively after the first
drug. Adverse events showed a moderate increase from the first to the last assigned drugs.
Reasons for drug withdrawal for each AED are provided in Table 4. The percentages of withdrawal
of carbamazepine, phenobarbital and valproate due to ineffectiveness were in general lower than the
percentages reported for other AEDs.
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Cumulative probabilities and predictors of withdrawal of the first, second and third AED
1. First AED. The cumulative probability of withdrawal of the first AED for ineffectiveness
increases from 2.9% at one year to 12.6% at twenty years (Supporting Table S1). The only predictor
was age at diagnosis: compared to those aged less than 15 years, those in the 15-64 year group were
less likely to withdraw due to ineffectiveness (HR 0.46, 95% CI 0.28-0.75), while those in the
oldest group showed no significant differences (HR 1.26, 95% CI 0.61-2.59). The cumulative
probability of withdrawing the first AED for terminal remission increased from 1.0% at one year to
20.0% at twenty years. The variables associated with first AED withdrawal due to seizure freedom
were age at diagnosis, sex and epilepsy syndrome. Compared to those aged less than 15 years, those
in the 15-64 year group were less likely to withdraw the drug (HR 0.58, 95% CI 0.40-0.86) while
those in the oldest group had a similar HR although this was not statistically significant. . Females
had a lower probability than males of withdrawing the drug (HR 0.56, 95% CI 0.39-0.82). Those
with cryptogenic/symptomatic epilepsies (HR 0.43, 95% CI 0.29-0.63) had a lower probability of
withdrawing the drug than those with idiopathic epilepsies. The cumulative probability of
withdrawing the first drug for adverse events was 0.5% at one year and increased to 3.3% at twenty
years. The probability of withdrawing the first drug for other reasons was 0.2% at one year and
6.6% at twenty years. Predictors for adverse events and other reasons were not assessed, due to the
small numbers. No significant differences were observed between old and new AEDs given as first
treatment (Supporting Table S2). Four hundred and sixty people never withdrew the first
antiepileptic treatment and 224 of them (50.9%) started a period of remission lasting until the end of
follow-up. The cumulative probability of either withdrawing the first AED for seizure freedom or of
achieving sustained remission while still on treatment was 23.1% at one year and increased to
48.0% at twenty years.
2. Second AED. The cumulative probability of withdrawing the second drug at twenty years for
ineffectiveness was 15.8%, for adverse events 4.3%, for terminal remission 13.3%, and for other
reasons 7.7% (Supporting Table S1). The only variable associated with discontinuation of the
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second AED for ineffectiveness was seizure type: compared to partial seizures, generalized seizures
were more likely to lead to drug withdrawal (HR 2.05, 95% CI 1.10-3.83). Due to the small number
of events, predictors for other reasons for the withdrawal of the second AED were not evaluated.
No significant differences were found between old and new AEDs (Supporting Table S2).
3. Third AED. The cumulative probability of withdrawing the third AED at twenty years for
ineffectiveness was 39.3%, for adverse events 8.0%, for seizure freedom 4.3%, and for other
reasons 5.0% (Supporting Table S1). Due to the small numbers, predictors for the third AED
withdrawal were not assessed. The comparison between old and new AEDs showed no significant
differences (Supporting Table S2).
Cumulative probabilities and predictors of withdrawal of the most commonly used AEDs
At 20 years, the cumulative time-dependent probability of withdrawal of carbamazepine for
ineffectiveness was 10.8%. The corresponding values were 13.5% for phenobarbital and 12.3% for
valproate (Figure 1A). The 20-year probability of withdrawal for terminal remission was 12.9% for
carbamazepine, 14.8% for phenobarbital and 27.4% for valproate (Figure 1B).
Predictors of withdrawal due to ineffectiveness were seizure type for carbamazepine and age for
phenobarbital. No predictors were found for valproate. Generalized seizures were more likely than
partial seizures to lead to withdrawal of carbamazepine for ineffectiveness (HR 3.07, 95% CI 1.35-
6.98). Individuals in the 15-64 years group had a lower probability of withdrawing phenobarbital
due to ineffectiveness than the youngest age group (HR 0.24, 95% CI 0.11-0.54), while those in the
oldest group showed no significant differences (HR 0.21, 95% CI 0.03-1.57).
Variables associated with drug withdrawal due to seizure freedom were sex for carbamazepine and
age, sex and syndrome for valproate. No predictors were found for phenobarbital. Females had a
lower probability of withdrawing carbamazepine for seizure freedom than males (HR 0.47, 95% CI
0.22-0.99). Compared to people in the <15 year group, those aged 15-64 years were less likely to
withdraw valproate due to ineffectiveness (HR 0.30, 95%CI 0.13- 0.70), while those in the oldest
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group showed no significant differences (HR 0.36, 95%CI 0.05-2.58); females had a lower
probability of withdrawing the drug than males (HR 0.52, 95% CI 0.30-0.91); compared with
idiopathic epilepsies, those with cryptogenic/symptomatic epilepsies were less likely to have drug
withdrawal (HR 0.35, 95% CI 0.19-0.65).
Due to the small number of events, cumulative probabilities and predictors of carbamazepine,
valproate and phenobarbital withdrawal for adverse events and other reasons were not assessed.
Discussion
People in our cohort, a representative sample of people with epilepsy in a defined area of Northern
Italy, have used a large number of AEDs over a 15-year period. However, during this time, the three
most common drugs given at the start of treatment were valproate, carbamazepine and
phenobarbital and only 10 percent of people started treatment with a new AED. Terminal remission
was the commonest explanation for discontinuation of the first drug (20% at twenty years),
followed by lack of efficacy (12.6%). Withdrawal of the first drug for adverse events was only
0.5% at one year and increased to 3.3% at twenty years. While the discontinuation of a drug for
terminal remission tended to decrease with AED order, treatment stop for ineffectiveness and for
adverse events tended to increase even though clear trends could not be detected because of the
small samples at the highest rankings. The reasons for drug withdrawal varied with age, sex and
disease characteristics.
The probability of retaining the first drug in the treatment schedule and starting a period of
remission lasting until the end of follow-up, or of stopping the first treatment for terminal
remission, was high, 48% at 20 years. Others found that the proportion of seizure-free individuals
on the first AED ranged from 5.4% to 62%;3,4,12,22-24 60.5% never withdrew the first AED and 51%
of them started a period of remission lasting until the end of follow-up. This finding supports the
concept that in clinical practice the majority of people with epilepsy can be easily controlled with
any of the available compounds even after long follow-up periods.
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In our study, the cumulative probability of discontinuing the first drug at 12 months for lack of
efficacy or adverse events was only 3.4%. Our findings are fairly similar to the results of a
Lebanese study of people with newly diagnosed focal epilepsy, which found a 12-month retention
rate of 93.6%.25 Our data only partly agree, however, with other long-term follow-up studies. In the
UK National General Practice Study of Epilepsy12 the first assigned drug was discontinued for lack
of efficacy in 21% of cases (compared to our 12.6%) but the discontinuation rate for adverse events
was 11.5% (compared to 3.3% in our study). This difference may be explained by the use of
carbamazepine, phenytoin, valproate or phenobarbital in 96% of the UK cases as compared to 87%
in our cohort. The use of fairly low daily doses for some drugs in our study (see Supporting Table
3) could be another explanation. No differences were found in retention rates when comparing old
and new AEDs. Our findings are in keeping with a study in children26 but differ from a study in
older adults27 in which the 12-month retention rates ranged from 12.5% (oxcarbazepine) to 90%
(valproate). In this latter study, however, the rates were calculated in people with refractory
epilepsy.
When comparing drugs in our study, differences in retention were seen. Discontinuation for lack of
efficacy was most common with GABAergic drugs while discontinuation for adverse events was
mostly seen with topiramate, phenytoin, carbamazepine and levetiracetam in decreasing order.
These findings are not unexpected even though the rates differ from those of other reports28-33 on
account of differing prescribing patterns and different populations at risk.
People in our cohort taking carbamazepine, valproate or phenobarbital discontinued the assigned
treatment for adverse events in 5.6, 1.1 and 2.8% of cases respectively. Our rates are significantly
lower than those reported by others (carbamazepine, valproate and lamotrigine stopped in 27, 13
and 10% of cases respectively).3 Possible explanations for this difference are the source population,
as the Scottish study was not population-based, and the use of different daily doses.
Children and elderly subjects tended to stop the first drug mostly for lack of efficacy and, less
frequently, due to terminal remission. Childhood and adolescent syndromes less responsive to the
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current treatments and the need to resort to complex therapeutic regimens in people with
comorbidities are possible explanations.
The lower rates of treatment withdrawal due to terminal remission in women than in men likely
reflects the higher proportion of females in the age class <15 years (59% versus 41% of male
children) who continued the first treatment, perhaps because of the fear of withdrawal in a period of
hormonal and emotional changes. As expected, people with idiopathic epilepsies and/or generalized
seizures were most likely to respond to the assigned treatments.
The study has strengths and limitations. The major strengths are the population base, the fairly large
sample size, and a long follow-up. In this regard, our findings apply to the general epilepsy
population in which, by definition, severe epilepsies are less frequent than in secondary and tertiary
referral centers. The major limitation is the uncontrolled setting. We do not know whether a drug
was discontinued after having been given at the highest tolerated dose. Our aim, however, was to
explore treatment changes as performed in clinical practice, where the selected daily dose generally
represents a compromise between seizure control, adverse events, and individual preference.
Another limitation is the time frame during which we started the follow-up. To include people with
newly diagnosed epilepsy in the cohort with reasonable follow-up, we started the observation at a
time in which mainly older AEDs were available. We are thus uncertain whether our findings apply
to cohorts starting treatment with a new AED. In keeping with our findings, however, there is no
evidence from more recent reports34-41 that new AEDs have advantages over older compounds.
Thus, we do not expect significant differences in other therapeutic contexts. Furthermore, the
cumulative time-dependent probability of withdrawal of AEDs other than carbamazepine,
phenobarbital and valproate was not assessed because of small numbers. The limited sample size
can also explain some non-significant correlations between demographic and clinical variables and
drug withdrawal. Lastly, we did our best to verify whether the indication for each drug was
appropriate. However, we cannot entirely exclude that drug failure was due to incorrect use of a
given drug in a given individual.
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In conclusion, the majority of people with epilepsy living in a community and followed for a
prolonged period of time remain treated with the first assigned drug. Seizure remission is the main
reason for drug discontinuation, followed by lack of efficacy and adverse events. Withdrawal of the
first drug for ineffectiveness and for adverse events tends to increase by AED order, while
decreasing for terminal remission. Withdrawal of the first AED for ineffectiveness can be predicted
by age at diagnosis while withdrawal of the second drug is predicted by seizure type, and reflects
the predominance of more severe epilepsy syndromes in younger individuals. These findings can
help the practicing physician to predict the response to the assigned treatment at diagnosis and when
a treatment change is required.
KEY POINTS
1. The initial antiepileptic drug (AED) given was retained in the majority of cases and only 10
percent of people started treatment with a new AED.
2. Reported reasons for AEDs withdrawal were, in decreasing order, terminal remission,
ineffectiveness and adverse events.
3. Discontinuation of a drug for terminal remission decreased with AED order; withdrawal for
ineffectiveness and adverse events increased.
4. Reasons for withdrawal varied with individuals’ age, sex, disease characteristics, and among
drugs.
5. The majority of people with epilepsy can be easily controlled with any of the available
compounds even after long follow-up periods.
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Table 1. General characteristics of the sample (n=747)
Variable Category N %
Gender W 366 49.0
M 381 51.0
Family history of Yes 111 14.9
Seizures* No 584 78.2
Unknown 52 6.9
Seizures Partial 460 61.6
Generalized 260 34.8
Unclassifiable 27 3.6
Syndrome GC/GS 74 9.9
GI 154 20.6
PC 167 22.4
PI 54 7.2
PS 265 35.5
Undetermined 26 0.9
Special 7 3.5
Age at diagnosis <15y 318 42.7
15-64y 353 47.4
65+y 74 9.9
Missing 2
Disease duration <1y 666 89.5
at diagnosis ≥1 y 78 10.5 
Missing 3
Number of AEDs 0 16 2.1
1 393 52.6
2 199 26.6
3 74 9.94+ 65 8.7
Legend: W women; M Men; GC/GS Generalized Cryptogenic/Generalized Symptomatic;
GI Generalized Idiopathic; PC Partial Cryptogenic;
PI Partial Idiopathic; PS Partial Symptomatic; y Years; AED Antiepileptic drug.
*Any type of seizures in all known relatives.
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Table 2. Administration frequency of first, second and third drug by active principle
First drug Second drug Third drug Fourth to ninthdrug
N % N % N % N
BSC 18 2.5 7 2.1 1 0.7 1
CBZ 203 27.8 60 17.8 18 12.9 4
CLB 2 0.3 22 6.5 12 8.6 7
CNP 2 0.3 31 9.2 8 5.8 16
ESM 9 1.2 4 1.2 4 2.9 2
GBP 2 0.3 6 1.8 4 2.9 6
LEV 13 1.8 32 9.5 18 12.9 29
LTG 4 0.5 32 9.5 13 9.4 15
OXC 31 4.2 16 4.7 5 3.6 10
PB 197 26.9 39 11.5 9 6.5 3
PHT 27 3.7 20 5.9 1 0.7 1
PGB 1 0.1 3 0.9 6 4.3 4
PRM 0 0.0 3 0.9 8 5.8 3
TGB 1 0.1 0 0.0 0 0.0 2
TPM 4 0.5 13 3.8 14 10.1 10
VGB 3 0.4 4 1.2 5 3.6 2
VPA 211 28.9 44 13.0 12 8.6 7
VPM 3 0.4 2 0.6 1 0.7 1
ZNS 0 0.0 0 0.0 0 0.0 3
Total N
patients* 731 338 139 65
Old AEDs 672 91.9 232 68.6 74 53.2 45
New
AEDs 59 8.1 106 31.4 65 46.8 81
AED Antiepileptic drugs, BSC Barbexaclone, CBZ Carbamazepine, CLB Clobazam,
CNP Clonazepam, ESM Ethosuximide, GBP Gabapentin, LEV Levetiracetam, LTG Lamotrigine,
OXC Oxcarbazepine, PB Phenobarbital, PHT Phenytoin, PGB Pregabalin, PRM Primidone,
TGB Tiagabine, TPM Topiramate, VGB Vigabatrin, VPA Valproate, VPM Valpromide,
ZNS Zonisamide.
*16 did not start drugs.
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Table 3. Reasons of drug withdrawal by order
Ranking Patientstreated
Ineffectivenes
s
Adverse
events
Terminal
remission Other*
Never
withdrawn
N N % N % N % N % N %
First 731** 83 11.3 20 2.7 117 16.0 45 6.2 460 62.9
Second 338** 45 13.3 11 3.2 24 7.1 20 5.9 232 68.6
Third 139 33 23.7 6 4.3 4 2.9 6 4.3 90 64.7
Fourth 65 22 33.8 3 4.6 0 0.0 2 3.1 38 58.5
Fifth 31 11 35.5 2 6.5 2 6.5 0 0.0 16 51.6
Sixth 18 6 33.3 0 0.0 1 5.6 0 0.0 11 61.1
Seventh 7 3 42.9 0 0.0 0 0.0 0 0.0 4 57.1
Eighth 3 0 0.0 2 66.7 0 0.0 0 0.0 1 33.3
Ninth 2 0 0.0 1 50.0 0 0.0 0 0.0 1 50.0
*Death, drug out of production, pregnancy, own volition.
** Missing information about AED withdrawal in six.
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Table 4. Frequency of reasons of drug withdrawal by active principle
Patients
treated Ineffectiveness Adverse events
Terminal
remission Other*
Never
withdrawn
N N % N % N % N % N %
BSC 27 6 22.2 1 3.7 4 14.8 9 33.3 7 25.9
CBZ 285 31 10.9 16 5.6 29 10.2 15 5.3 194 68.1
CLB 43 12 27.9 0 0.0 2 4.7 2 4.7 27 62.8
CNP 57 6 10.5 1 1.8 1 1.8 2 3.5 47 82.5
ESM 19 4 21.1 0 0.0 6 31.6 0 0.0 9 47.4
GBP 18 12 66.7 0 0.0 0 0.0 0 0.0 6 33.3
LEV 92 12 13.0 5 5.4 3 3.3 0 0.0 72 78.3
LTG 64 15 23.4 1 1.6 2 3.1 4 6.3 42 65.6
OXC 62 10 16.1 3 4.8 5 8.1 3 4.8 41 66.1
PB 248 34 13.7 7 2.8 34 13.7 23 9.3 150 60.5
PHT 49 16 32.7 3 6.1 2 4.1 4 8.2 24 49.0
PGB 14 1 7.1 0 0.0 0 0.0 2 14.3 11 78.6
PRM 14 2 14.3 0 0.0 1 7.1 1 7.1 10 71.4
TGB 3 2 66.7 1 33.3 0 0.0 0 0.0 0 0.0
TPM 41 11 26.8 4 9.8 4 9.8 1 2.4 21 51.2
VGB 14 7 50.0 0 0.0 2 14.3 0 0.0 5 35.7
VPA 274 27 9.9 3 1.1 55 20.1 8 2.9 181 66.1
VPM 7 0 0.0 0 0.0 1 14.3 1 14.3 5 71.4
ZNS 3 0 0.0 0 0.0 0 0.0 0 0.0 3 100.0
Old AEDs 1023 138 13.5 31 3.0 135 13.2 66 6.5 654 63.9
New AEDs 311 70 22.2 14 4.5 16 5.1 10 3.2 201 64.6
AED Antiepileptic drug, BSC Barbexaclone, CBZ Carbamazepine, CLB Clobazam, CNP Clonazepam, ESM Ethosuximide,
GBP Gabapentin, LEV Levetiracetam, LTG Lamotrigine, OXC Oxcarbazepine, PB Phenobarbital, PHT Phenytoin,
PRG Pregabalin, PRM Primidone, TGB Tiagabine, TPM Topiramate, VGB Vigabatrin, VPA Valproate, VPM Valpromide,
ZNS Zonisamide. * Death, drug out of production, pregnancy, own volition withdrawal.
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Figure 1. Cumulative incidence functions for withdrawal of carbamazepine, phenobarbital
and valproate, for ineffectiveness (A) and terminal remission (B)
